NCT04764669

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

An Open-Label Study To Evaluate the Pharmacodynamic Effects, Efficacy, Safety, and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies or Parkinson's Disease Dementia With or Without Amyloid Copathology

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9 weeks of treatment.

Conditions

• Lewy Body Disease
• Parkinson Disease

Interventions

Type	Name	Description
DRUG	E2027	Oral hypromellose capsules.

Timeline

• Start date: 2021-02-25
• Primary completion: 2021-12-08
• Completion: 2022-01-27
• First posted: 2021-02-21
• Last updated: 2022-09-26
• Results posted: 2022-09-26

Locations

14 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study